Vestiage, Inc.

VEST

US92548W1053

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 11:56:04 2024-04-23 am EDT			5-day change	1st Jan Change
0.021 ^USD	-79.00%		-79.00%	+4.48%

Apr. 16	Vestiage, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Vestiage, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Vestiage, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023

November 21, 2023 at 10:41 am EST

Vestiage, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported net loss was USD 0.010132 million compared to USD 0.00662 million a year ago.
For the nine months, net loss was USD 0.046323 million compared to USD 0.03957 million a year ago.

Latest news about Vestiage, Inc.

Vestiage, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 16	CI
Vestiage, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 21	CI
Vestiage, Inc. Announces CEO Changes	23-08-29	CI
Vestiage, Inc. Appoints Raymond Fu as its CFO	23-08-29	CI
Vestiage, Inc. Announces Executive Changes	23-08-29	CI
Vestiage, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-04	CI
Vestiage, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Vestiage, Inc. Provides Earnings Guidance for the Fourth Quarter of 2014	15-02-01	CI
Vestiage, Inc. cancelled the transaction announced on December 20, 2013.	14-12-19	CI
Vestiage, Inc. Announces the Availability of Regimen Products in Vitamin Shoppe Retail Stores	14-09-09	CI
Vestiage Announces Executive Appointments	14-09-04	CI
Vestiage, Inc. Receives Purchase Order from The Vitamin Shoppe	14-08-26	CI
Vestiage, Inc. Announces Unaudited Earnings Results for the Second Quarter and Six Months Ended June 30, 2014	14-08-14	CI
Empowered Products, Inc. and Vestiage, Inc. Enter Joint Marketing Agreement	14-07-08	CI
Vestiage, Inc. announced that it has received funding from Media Funding Group.	14-06-25	CI
Vestiage Inc. Appoints Laura Stall to National VP of Sales	14-06-19	CI
Vestiage, Inc. announced that it has received funding from Media Funding Group.	14-05-08	CI
Vestiage, Inc. Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2014	14-05-06	CI
Vestiage, Inc. Reveals Two New Products	14-04-02	CI
Vestiage, Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2013	14-03-11	CI
Vestiage, Inc. Names Laura Stall as Vice President, Nutraceuticals Sales, Western Region	14-02-10	CI
Vestiage's RegiMEN(TM) Brand to Be Distributed by Europa Sports Products	14-01-30	CI
Vestiage Adds to Advisory Committee in Fourth Quarter	13-12-30	CI
Vestiage, Inc. announced that it expects to receive $4.38 million in funding.	13-12-19	CI
Vestiage, Inc. announced that it has received funding	13-10-01	CI

Chart Vestiage, Inc.

Duration

Period

More charts

Company Profile

Vestiage, Inc. is a developmental stage company. The Company is in the fitness event planning industry. The Company specialize in the planning of events and competitions for fitness gyms within the functional fitness space. It sponsors competitions within local communities and organize events, such as parties and educational seminars. Its services include competition planning, vendor organization, food services, securing competition equipment and volunteers to work the event. It also plans parties for local gyms such for holiday and new member celebrations. The Companyâs subsidiary is Fun Fitness Corporation.

Sector

Pharmaceuticals

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VESTIAGE, INC.	+4.48%	1.22M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B